SCHEMBL23880679

SCHEMBL23880679

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@H](O)[C@H]1OCl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 4/20 0.75
▸ ADORA1 P30542 2/20 0.75
▸ PI4KA P42356 2/20 0.75
▸ PI4K2B Q8TCG2 2/20 0.75
▸ PI4K2A Q9BTU6 2/20 0.75
▸ PI4KB Q9UBF8 2/20 0.75
▸ DPP4 P27487 1/20 0.75
▸ MEN1 O00255 1/20 0.75
▸ SLC28A1 O00337 1/20 0.75
▸ MAP3K7 O43318 1/20 0.75
▸ SLC28A2 O43868 1/20 0.75
▸ GAPDH P04406 1/20 0.75
▸ MAPK1 P28482 1/20 0.75
▸ ADORA2A P29274 1/20 0.75
▸ ADORA2B P29275 1/20 0.75
▸ STAT6 P42226 1/20 0.75
▸ KMT2A Q03164 1/20 0.75
▸ SMN1; SMN2 Q16637 1/20 0.75
▸ DOT1L Q8TEK3 1/20 0.75
▸ SLC29A1 Q99808 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6658365 1.00 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL546471 0.90 ADORA3 (0.77) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL6142045 0.90 ADORA3 (0.77) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL26130573 0.90 ADORA3 (0.77) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL5053230 0.90 ADORA3 (0.77) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL25936 0.89 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL24538798 0.89 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL25937 0.89 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL23050294 0.89 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A
SCHEMBL12150808 0.89 ADORA3 (0.75) ADORA3ADORA1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117677698-A Oligonucleotides for neuromuscular disorders and compositions thereof 米雷楚来股份有限公司 2024-03-08 — — CN disclosed
CN-116096890-A Targeted inhibition using engineered oligonucleotides 米雷楚莱股份有限公司 2023-05-09 — — CN disclosed
US-20210308283-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNA THERAPEUTICS, INC. 2021-10-07 — — US disclosed
CN-110511939-A Nucleosides, nucleotide and nucleic acid of modification and application thereof MODERNATX INC 2019-11-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210308283-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 ADORA3 103/4885ADORA1 161/4885PI4KA 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback